These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15144930)

  • 41. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
    Sarafidis PA; Bakris GL
    J Clin Hypertens (Greenwich); 2006 May; 8(5):351-6; quiz 357-8. PubMed ID: 16687944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.
    Wendt T; van der Does R; Schräder R; Landgraf H; Kober G
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S147-50. PubMed ID: 2454362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.
    Yue TL; Mckenna PJ; Gu JL; Cheng HY; Ruffolo RR; Feuerstein GZ
    Hypertension; 1993 Dec; 22(6):922-8. PubMed ID: 7902335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients.
    Bakovic D; Pivac N; Eterovic D; Palada I; Valic Z; Paukovic-Sekulic B; Dujic Z
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):441-6. PubMed ID: 19702597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade.
    Grimm D; Huber M; Jabusch HC; Shakibaei M; Fredersdorf S; Paul M; Riegger GA; Kromer EP
    J Mol Cell Cardiol; 2001 Mar; 33(3):487-501. PubMed ID: 11181017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
    Lund-Johansen P
    Clin Nephrol; 1992; 38 Suppl 1():S78-86. PubMed ID: 1363538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does beta 1-selective agonistic activity interfere with the antihypertensive efficacy of beta 1-selective blocking agents?
    Leonetti G; Sampieri L; Cuspidi C; Terzoli L; Rupoli L; Fruscio M; Gradnik R; Zanchetti A
    J Hypertens Suppl; 1985 Dec; 3(3):S243-5. PubMed ID: 2908819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beta-blockers in hypertension.
    Ram CV
    Am J Cardiol; 2010 Dec; 106(12):1819-25. PubMed ID: 21126627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients.
    Jonsson G; Abdelnoor M; Müller C; Kjeldsen SE; Os I; Westheim A
    Cardiology; 2005; 103(3):148-55. PubMed ID: 15785019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.
    Sica DA; Black HR
    Curr Hypertens Rep; 2008 Aug; 10(4):330-5. PubMed ID: 18625165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-blockers in 2007?
    Straughan JL
    Cardiovasc J Afr; 2007; 18(2):90-2. PubMed ID: 17497045
    [No Abstract]   [Full Text] [Related]  

  • 54. Antihypertensive treatment with a dual-acting beta-blocker in the elderly.
    Lessem JN; Weber MA
    J Hypertens Suppl; 1993 Jun; 11(4):S29-36. PubMed ID: 8104239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.
    Kveiborg B; Christiansen B; Major-Petersen A; Torp-Pedersen C
    Am J Cardiovasc Drugs; 2006; 6(4):209-17. PubMed ID: 16913822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper.
    Yue TL; McKenna PJ; Lysko PG; Ruffolo RR; Feuerstein GZ
    Atherosclerosis; 1992 Dec; 97(2-3):209-16. PubMed ID: 1361324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical updates on carvedilol: a first choice beta-blocker in the treatment of cardiovascular diseases.
    Chakraborty S; Shukla D; Mishra B; Singh S
    Expert Opin Drug Metab Toxicol; 2010 Feb; 6(2):237-50. PubMed ID: 20073998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacology of carvedilol.
    Ruffolo RR; Gellai M; Hieble JP; Willette RN; Nichols AJ
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S82-8. PubMed ID: 1974511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beta-blockers use for hypertension in the elderly.
    Herrera J
    Cardiovasc Hematol Agents Med Chem; 2015; 12(3):152-9. PubMed ID: 25761100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils.
    Yue TL; McKenna PJ; Ruffolo RR; Feuerstein G
    Eur J Pharmacol; 1992 Apr; 214(2-3):277-80. PubMed ID: 1355437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.